Patents by Inventor Leo A. Trevino
Leo A. Trevino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100305175Abstract: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v, a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 200-400 mOsm/kG, at a pH between 4 to 8, wherein the latrunculin, the surfactant, and the tonicity agent are compatible in the formulation, and the formulation does not contain a substantial amount of dimethyl sulfoxide. The formulation is stable for at least six month at refrigerated temperature. The present invention further provides a method of reducing intraocular pressure, a method of treating glaucoma, a method of inhibiting wound healing after trabeculectomy, and a method of inhibiting angiogenesis.Type: ApplicationFiled: August 13, 2010Publication date: December 2, 2010Inventors: Ramesh Krishnamoorthy, Leo A. Trevino, Richard M. Evans
-
Patent number: 7785624Abstract: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v, a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 200-400 mOsm/kG, at a pH between 4 to 8, wherein the latrunculin, the surfactant, and the tonicity agent are compatible in the formulation, and the formulation does not contain a substantial amount of dimethyl sulfoxide. The formulation is stable for at least six month at refrigerated temperature. The present invention further provides a method of reducing intraocular pressure, a method of treating glaucoma, a method of inhibiting wound healing after trabeculectomy, and a method of inhibiting angiogenesis.Type: GrantFiled: March 1, 2007Date of Patent: August 31, 2010Assignee: Inspire Pharmaceuticals, Inc.Inventors: Ramesh Krishnamoorthy, Leo A. Trevino, Richard M. Evans, Carole Evans, legal representative
-
Publication number: 20100022517Abstract: The present invention relates to an aqueous pharmaceutical formulation comprising at least one inhibitor of Rho-associated protein kinase (ROCK). The aqueous pharmaceutical formulation comprises 0.01-0.4% w/v of ROCK inhibitor(s), a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 220-360 mOsm/kG, at a pH between 6.3 to 7.8, wherein the ROCK inhibitor, the surfactant, and the tonicity agent are compatible in the formulation. The aqueous ophthalmic formulations of this invention have an increased ocular bioavailability and/or aqueous humor concentrations without a concomitant increase in systemic concentrations. The present invention further provides a method of reducing intraocular pressure, particularly a method of treating glaucoma, by administering the aqueous pharmaceutical formulation to a subject.Type: ApplicationFiled: June 11, 2009Publication date: January 28, 2010Inventors: Lori A. Richards, Christopher S. Crean, Ward M. Peterson, Leo A. Trevino
-
Publication number: 20070225343Abstract: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v, a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 200-400 mOsm/kG, at a pH between 4 to 8, wherein the latrunculin, the surfactant, and the tonicity agent are compatible in the formulation, and the formulation does not contain a substantial amount of dimethyl sulfoxide. The formulation is stable for at least six month at refrigerated temperature. The present invention further provides a method of reducing intraocular pressure, a method of treating glaucoma, a method of inhibiting wound healing after trabeculectomy, and a method of inhibiting angiogenesis.Type: ApplicationFiled: March 1, 2007Publication date: September 27, 2007Inventors: Ramesh Krishnamoorthy, Leo Trevino, Richard Evans
-
Patent number: 7141235Abstract: A gas emulsion forming composition comprising a dry, hollow, particulate, approximately microspherical material permeated with a gas or gas mixture, which upon dissolution in aqueous liquid forms a gas emulsion comprising a plurality of bubbles surrounded by a layer of at least a first and a second surfactant, wherein the first surfactant consists essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, and wherein the second surfactant may or may not be a phospholipid and is more water soluble than the first surfactant; kits for preparing such microbubbles; and methods for using such microbubbles as contrast agents.Type: GrantFiled: August 28, 2001Date of Patent: November 28, 2006Assignee: Imcor Pharmaceutical Co.Inventors: Leo A. Trevino, Ernest George Schutt, David H. Klein, Thomas E. Tarara, Jeffry G. Weers, Alexey Kabalnov
-
Publication number: 20020031476Abstract: A gas emulsion forming composition comprising a dry, hollow, particulate, approximately microspherical material permeated with a gas or gas mixture, which upon dissolution in aqueous liquid forms a gas emulsion comprising a plurality of bubbles surrounded by a layer of at least a first and a second surfactant, wherein the first surfactant consists essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, and wherein the second surfactant may or may not be a phospholipid and is more water soluble than the first surfactant; kits for preparing such microbubbles; and methods for using such microbubbles as contrast agents.Type: ApplicationFiled: August 28, 2001Publication date: March 14, 2002Inventors: Leo A. Trevino, Ernest George Schutt, David H. Klein, Thomas E. Tarara, Jeffry G. Weers, Alexey Kabalnov
-
Patent number: 6280705Abstract: A gas emulsion forming composition comprising a dry, hollow, particulate, approximately microspherical material permeated with a gas or gas mixture, which upon dissolution in aqueous liquid forms a gas emulsion comprising a plurality of bubbles surrounded by a layer of at least a first and a second surfactant, wherein the first surfactant consists essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, and wherein the second surfactant may or may not be a phospholipid and is more water soluble than the first surfactant; kits for preparing such microbubbles; and methods for using such microbubbles as contrast agents.Type: GrantFiled: January 26, 1998Date of Patent: August 28, 2001Assignee: Alliance Pharmaceutical Corp.Inventors: Leo A. Trevino, Ernest George Schutt, David H. Klein, Thomas E. Tarara, Jeffry G. Weers, Alexey Kabalnov
-
Patent number: 5874481Abstract: A thermodynamically stable molecular solution providing enhanced bioavailability for lipophilic pharmaceutical agents, comprising a liquid carrier comprising one or more physiologically acceptable lipophilic fluorochemicals, and a pharmaceutically effective amount of at least one lipophilic pharmaceutical agent in said liquid carrier to form a thermodynamically stable molecular solution, optionally also including a co-solvent for facilitating solubilization of the pharmaceutical agent. Methods of making and using the molecular solution are also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: February 23, 1999Assignee: Alliance Pharmaceutical Corp.Inventors: Jeffry G. Weers, Luis A. Dellamary, Thomas E. Tarara, Leo A. Trevino, Helen M. Ranney
-
Patent number: 5798091Abstract: A gas emulsion forming composition comprising a dry, hollow, particulate, approximately microspherical material permeated with a gas or gas mixture, which upon dissolution in aqueous liquid forms a gas emulsion comprising a plurality of bubbles surrounded by a layer of at least a first and a second surfactant, wherein the first surfactant consists essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, and wherein the second surfactant may or may not be a phospholipid and is more water soluble than the first surfactant; kits for preparing such microbubbles; and methods for using such microbubbles as contrast agents.Type: GrantFiled: February 28, 1995Date of Patent: August 25, 1998Assignee: Alliance Pharmaceutical Corp.Inventors: Leo A. Trevino, Ernest George Schutt, David H. Klein, Thomas E. Tarara, Jeffry G. Weers, Alexey Kabalnov
-
Patent number: 5733526Abstract: Novel hydrocarbon oil/fluorochemical preparations and methods for their use are provided. The preparations, which preferably comprise a fluorophilic dispersing agent, may be in the form of hydrocarbon oil-in-fluorochemical dispersions or in the form of a multiple emulsion comprising a polar liquid continuous phase and are particularly useful for administering bioactive agents. In particular the preparations of the present invention may be used to control the bioavailability and improve the efficacy of lipophilic bioactive agents having limited solubility in an aqueous physiological environment.Type: GrantFiled: December 14, 1995Date of Patent: March 31, 1998Assignee: Alliance Pharmaceutical Corp.Inventors: Leo A. Trevino, Jean G. Riess, Luis A. Dellamary, Marie-Pierre Krafft, Thomas E. Tarara
-
Patent number: 5667809Abstract: A method for preparing a pharmaceutical microdispersion exhibiting enhanced bioavailability, including the steps of providing a thermodynamically stable pharmaceutical composition comprising at least one lipophilic pharmaceutical agent incorporated in a physiologically acceptable liquid carrier, the liquid carrier comprising one or more lipophilic solvents such as fluorochemicals and preferably at least one nonfluorinated co-solvent, and combining the stable pharmaceutical composition with an amount of at least one miscible diluent sufficient to initiate phase separation of the lipophilic pharmaceutical agent from the pharmaceutical composition wherein a microdispersion of the pharmaceutical composition is formed. Also disclosed are microdisperse pharmaceutical compositions and kits for forming such compositions.Type: GrantFiled: June 7, 1995Date of Patent: September 16, 1997Assignee: Alliance Pharmaceutical Corp.Inventors: Leo A. Trevino, Luis A. Dellamary, Thomas E. Tarara, Jeffry G. Weers, Helen M. Ranney